B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $85 to $80.
B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $85 to $80.